Images List Premium Download Classic

Quinoline

Quinoline-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Quinoline derivative
Ono Pharmaceutical Co., Ltd.
December 07, 2017 - N°20170349583

A compound represented by general formula (i) and having a quinoline skeleton has a strong axl inhibitory activity, and therefore the compound can be an agent for treating axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
Composition and method for treating skin conditions
442 Ventures, Llc
November 30, 2017 - N°20170340625

Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.
Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
Epizyme, Inc.
November 23, 2017 - N°20170334861

Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity. Methods of using the compounds for treating prmt5-mediated disorders are also described.
Quinoline Patent Pack
Download 195+ patent application PDFs
Quinoline Patent Applications
Download 195+ Quinoline-related PDFs
For professional research & prior art discovery
inventor
  • 195+ full patent PDF documents of Quinoline-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
4-oxoquinoline compounds
Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v
November 16, 2017 - N°20170331049

Provided is a 4-oxoquinoline compounds of the formula (i) (i) wherein a is selected from diradicals of the formulae (a. 1), (a. 2), (a. 3), (a. 4), (a. 5) and (a. 6), (a. 1) (a. 2) (a. 3) (a. 4) (a. 5) (a. 6) wherein r1, r2a, r2b, r3, r3a, if present r4a, r4b, r5a, r5b, r6a, r6b, r6c, r6d, rn1, ...
4-hydroxyquinoline compounds
Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v
November 16, 2017 - N°20170327465

Wherein a is selected from diradicals of the formulae (a. 1), (a. 2), (a. 3), (a. 4), (a. 5), and (a. 6) wherein r1, r2a, r2b, r3, if present r4a, r4b, r5a, r5b, r6a, r6b, r6c, r6d, rn1, rn2, rn3, rn4, rm5, rm6, rm7, rm8, r7, r8a, r9 are as defined in the description.
Crystals of laquinimod sodium and improved process for the manufacture thereof
Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v
November 16, 2017 - N°20170327464

F) an amount of methyl 5-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylate (mcqme) in the mixture is no more than 0. 12% relative to the amount of laquinimod sodium as measured by hplc.
Quinoline Patent Pack
Download 195+ patent application PDFs
Quinoline Patent Applications
Download 195+ Quinoline-related PDFs
For professional research & prior art discovery
inventor
  • 195+ full patent PDF documents of Quinoline-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
Auspex Pharmaceuticals, Inc.
November 09, 2017 - N°20170320871

And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituent and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula i compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen ...
Quinoline carboxamides for use in the treatment of leukemia
Active Biotech Ab
November 09, 2017 - N°20170319568

A compound of formula (i) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.
Isoquinolin-3-yl carboxamides and preparation and use thereof
Active Biotech Ab
November 02, 2017 - N°20170313682

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e. G., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by ...
Isoquinolin-3-yl carboxamides and preparation and use thereof
Active Biotech Ab
November 02, 2017 - N°20170313681

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e. G., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated ...
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
Active Biotech Ab
November 02, 2017 - N°20170313678

The present invention relates to a crystalline form of n-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions ...
Substituted naphthyridine and quinoline compounds as mao inhibitors
Active Biotech Ab
November 02, 2017 - N°20170312263

Wherein r1, r2, r3, y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting mao, and mao-b selectively, enhancing neuronal plasticity, treating neurological disorders, ...
Tyrosine hydroxylase variants and methods of use thereof
The Regents Of The University Of California
October 26, 2017 - N°20170306301

The present disclosure provides a variant tyrosine hydroxylase that provides for increased production of l-dopa in a host cell that expresses the tyrosine hydroxylase. The present disclosure provides nucleic acids encoding the variant tyrosine hydroxylase, and host cells genetically modified with the nucleic acids. The present disclosure provides methods of making l-dopa in a host cell. The present disclosure provides ...
Quinoline Patent Pack
Download 195+ patent application PDFs
Quinoline Patent Applications
Download 195+ Quinoline-related PDFs
For professional research & prior art discovery
inventor
  • 195+ full patent PDF documents of Quinoline-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrahydronaphthyridine derivatives as mglur2-negative allosteric modulators, compositions, and their use
Merck Canada Inc.
October 26, 2017 - N°20170305902

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (i) or a pharmaceutically acceptable salt thereof, wherein r1, r2, l, x1, x2, and x3, are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and may ...
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
Merck Canada Inc.
October 26, 2017 - N°20170305880

Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments.
Tetrahydroisoquinoline derivatives
Ucb Biopharma Sprl
October 26, 2017 - N°20170304292

The present invention relates to tetrahydroisoquinoline derivatives according to formula (i), which are positive allosteric modulators of d1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which d1 receptors play a role.
Quinoline derivative against non-small cell lung cancer
Advenchen Laboratories Nanjing Ltd.
October 26, 2017 - N°20170304290

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1h-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without ...
Formulations of methionine aminopeptidase inhibitors for treating infectious diseases
Texas Southern University
October 26, 2017 - N°20170304288

Provided herein are formulations and co-solvent formulations and methods for treating an infectious disease utilizing the same. The formulations and co-solvent formulations may comprise a hydroxyquinoline analog or its pharmaceutically acceptable salt, a solvent and at least two surfactants. Also provided are methods of quantitating a hydroxyquinoline analog in a sample via chromatographic/spectrometric measurements.
Oligomeric quinoline compounds for tackifying pressure sensitive adhesives
Texas Southern University
October 19, 2017 - N°20170298256

Described herein is an adhesive composition comprising: (a) a (meth)acryloyl polymer; and (b) greater than 1 parts of a tackifier per 100 parts of the(meth)acryloyl polymer, wherein the tackifier comprises a substituted oligomeric quinoline.
Tetrahydroisoquinoline derived prmt5-inhibitors
Texas Southern University
October 19, 2017 - N°20170298075

A compound of formula i wherein: n is 1 or 2: p is 0 or 1; r1 is optionally one or more halo or methyl groups; r2a and r2b are independently selected from the group consisting of: (i) f; (ii) h; (iii) me; and (iv) ch2oh; r2c and r2d are independently selected from the group consisting of: (i) f; (...
Tetrahydroquinoline derivatives as bromodomain inhibitors
Texas Southern University
October 19, 2017 - N°20170298047

The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
Loading